Drug Trial Radar · NCT06556810
IC14 for Treatment of Acute Decompensated Heart Failure
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Oct 17, 2024
Primary completion
Aug 30, 2026
Study completion Oct 1, 2026
Sponsor
- Lead sponsor
- Implicit BioscienceIndustry
- Sponsor type
- Industry
- Collaborators
- University of Virginia; Virginia Commonwealth University
- First posted
- Aug 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug atibuclimab (IC14) works to treat adults hospitalized with acute decompensated heart failure (ADHF). It will also learn about the safety of IC14. The main questions it aims to answer are: Is the drug IC14 safe in patients with ADHF? What are the IC14 drug levels in the bloodstream after treatment with IC14? What is the impact of IC14 treatment on markers of disease in the bloodstream? What is the impact of IC14 treatment on measures of heart failure? There is no placebo arm in this study. Participants will: Take drug IC14 once via an intravenous infusion After the infusion, be visited in the hospital or visit the clinic 5 times for checkups and tests Answer questions about their medical status via a phone call 3 months after the infusion
Conditions
- Acute Decompensated Heart Failure
Interventions
Atibuclimab (IC14)Drug
Atibuclimab (IC14) is a monoclonal antibody against human cluster of differentiation (CD)14, a key signaling molecule of the innate immune system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of IC14 treatmentTime frame: 0-28 days
- Anti-Drug Antibodies following IC14 treatmentTime frame: 0-28 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Virginia
Charlottesville, Virginia
Virginia Commonwealth University
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.